(Información remitida por la empresa firmante)
This press release contains forward-looking statements that reflect Immunovia AB (publ)’s current view of future events as well as financial and operational development. Words such as “intend”, “assess”, “expect”, “may”, “plan”, “estimate” and other expressions involving indications or predictions regarding future development or trends, not based on historical facts, identify forward-looking statements and reflect Immunovia AB (publ)’s beliefs and expectations and involve a number of risks, uncertainties and assumptions which could cause actual events and performance to differ materially from any expected future events or performance expressed or implied by the forward-looking statement. The information contained in this press release is subject to change without notice and, except as required by applicable law, Immunovia AB (publ) does not assume any responsibility or obligation to update publicly or review any of the forward-looking statements contained in it and nor does it intend to. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. As a result of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements as a prediction of actual future events or otherwise. 1 US Pancreatic Cancer Action Network. New Early Detection Blood Tests: What to Know. 2021. https://pancan.org/news/new-early-detection-blood-tests-what-to-know.
2 US Pancreatic Cancer Action Network. New Early Detection Blood Tests: What to Know. 2021. https://pancan.org/news/new-early-detection-blood-tests-what-to-know.
3 Of the Company’s assessment of the total addressable market of over 1.8 million patients, approximately 600,000 are attributable to individuals with a familial/hereditary risk of pancreatic cancer, over 1 million patients attributable to the high-risk group of newly diagnosed diabetes after the age of 50 and approximately 200,000 individuals attributable to the high-risk group with early vague symptoms.
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/immunovia-resolves-on-a-rights-issue-of-approximately-sek-202-2-million-and-postpones-the-publication-of-the-quarterly-report-for-the-first-quarter-and-the-annual-general-meeting-301750534.html